AGN 211377

a prostaglandin receptor and thromboxane A2 receptor antagonist; structure in first source

Also Known As:

3-(2-(3-(4-(4-cyclohexylbutylcarbamoyl)oxazol-2-yl)-7-oxabicyclo(2.2.1)hept-2-ylmethyl)-4-fluorophenyl)acrylic acid

Networked: 1 relevant articles (0 outcomes, 1 trials/studies)

1.	Inflammation (Inflammations) 01/01/2017 - "Consistent with previous polypharmacological studies on chemokine/cytokine release from human macrophages, the prostanoid EP1 receptor played a permissive role in suppressing neovascularization and inflammation in vivo Comparing AGN 211377 with a close structural congener lacking EP1 antagonism (AGN 197727), AGN 197727 was much less active than AGN 211377, but pronounced anti-inflammatory and angiostatic effects were achieved by adding the EP1 antagonist compound (SC-51322) to AGN 197727 in the systemic dosing regimen. "
2.	Retinal Neovascularization 01/01/2017 - "Whereas compounds selective for a single prostanoid receptor typically exhibited modest but statistically significant inhibition, AGN 211377 profoundly inhibited S-antigen-induced uveitis and laser-induced retinal neovascularization. "
3.	Uveitis 01/01/2017 - "A compound such as AGN 211377 may represent more effective therapy than COX inhibitors in treating uveitis and ocular diseases where neovascularization is a significant part of the pathology.-Woodward, D. " 01/01/2017 - "Whereas compounds selective for a single prostanoid receptor typically exhibited modest but statistically significant inhibition, AGN 211377 profoundly inhibited S-antigen-induced uveitis and laser-induced retinal neovascularization. "